Medidata Blog

Ni Hao from Shanghai! 上海的你好

Reading Time: 4 minutes

A sellout crowd of over 130 people attended the largest China Symposium to date, helping make it a phenomenal success from every perspective. With the room filled to capacity, extra seating had to be provided to enable more attendees than expected to join the conversations and talk about how the Medidata Clinical Cloud is indeed transforming clinical development! Takeru Yamamoto, managing director for Medidata APAC opened the session in Mandarin, setting the tone for a highly collaborative and informative day. The keynote speech from Veronica Xia of Kun Tuo (China-based CRO part of Quintiles) and Edwin Ng of Medidata (APAC vice president of sales) helped emphasize the incredible growth opportunity in the region, while pointing out some of the challenges. MedidataSymposiumChina_1 In just the last few years, the growth in clinical trials and research being done in China makes it the fastest growing market, and will soon be the largest in the world. Our clients recognize this opportunity, and are putting Medidata Solutions at the center of their growth strategy. While this is exciting, this growth comes with some challenges. Given the diversity of investigator experience, staff turnover, changing regulatory landscape, long approval process and different standards of care than those in other parts of the world, it is essential that technology solutions be flexible, extendable and innovative enough to harness this growth. In a case study showing how Medidata Solutions platform solutions are designed to enable partners and sponsors to successfully overcome these challenges in late phase research, Dr Na Zhao of Novartis demonstrated how the intuitive user interface and navigation, on-line/on-demand training modules, real-time data access, and flexible design options make the Medidata Clinical Cloud a perfect fit for APAC trials in China. In her closing comments, Dr Na Zhao pointed out that innovations like the patient cloud and device integration make it possible for sponsors to move from bringing the patient to the trial to bringing the trial to the patient – a key objective for Novartis. The two breakout sessions were led by yours truly with Ji Li, “More about Rave,” and Zhiyang Chen with Tom Billow presented “Enhanced Tools for Study Implementation”. Both were well attended and provided clients, partners and prospective clients with opportunities to grill our subject matter experts on how to take advantage of the platform in China. I began my session in Mandarin much to the delight of the attendees (and chagrin of the translators), but settled into English as the session got into details of how to take advantage of Rave capabilities and the platform. Chen’s session with Tom was very well received and provided lots of details about how to best implement studies on the platform. The sessions were followed by a lively panel discussion led by Tom Billow of Medidata, Andrew Taylor from Roche and Yazhong Deng from Covance. Much of the discussion centered on the opportunities and details of risk-based monitoring and how it benefits clients in China. Yazhong_Ross                                   As we watched the sunset behind the famous landmark Oriental Pearl Tower in Shanghai and the city lights flashed and sparkled across the skyline, it was clear that our clients, partners and especially patients in China have a bright and exciting future. Xia xia nong 下下侬 Thank you! *Guest blogger Ross Rothmeier is a VP of technology solutions at Medidata. You can reach Ross by email or follow him on Twitter @RossClinCloud. TWEET THIS:

The fastest growing #clinicaltrials market in Asia, China will soon be the largest in the world! #MedidataSYM — Medidata (@Medidata) September 9, 2014


Medidata Solutions Image

Medidata Solutions